Compumedics (ASX:CMP) reported record sales orders taken of AU$32.8 million for the first half of fiscal 2025, up 55% year on year, according to a Wednesday filing with the Australian bourse.

The total does not include the company's MEG brain imaging technology.

The US division drove growth as sales surged 208%, the filing said. Asian booked sales orders rose 115%, while European sales grew 10%.

The medical device maker expects reported revenue of AU$23.2 million for the first half, down 13% on the year-earlier period. Excluding MEG, first-half revenue is forecast to be 6% higher year on year.

For fiscal 2025, the company anticipates sales of more than AU$55 million, excluding MEG. It also expects earnings before interest, taxes, depreciation, and amortization of above AU$5 million.

Compumedics' shares rose almost 11% in recent Wednesday trade.